TD Cowen analyst Marc Frahm raised the firm’s price target on Royalty Pharma (RPRX) to $50 from $45 and keeps a Buy rating on the shares. The firm says Royalty Pharma is poised to benefit from unique strengths, including growth of the biopharma royalty market, differentiation from its competitors, and diversification of its portfolio. To reflect these and other tailwinds, TD Cowen has updated its model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
- Royalty Pharma Earnings Call Balances Strength And Risk
- Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
- Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
- Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B